These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 23543667)

  • 1. Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy.
    Ganly I; Ricarte Filho J; Eng S; Ghossein R; Morris LG; Liang Y; Socci N; Kannan K; Mo Q; Fagin JA; Chan TA
    J Clin Endocrinol Metab; 2013 May; 98(5):E962-72. PubMed ID: 23543667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid Hürthle cell tumors: research of potential markers of malignancy.
    Donatini G; Beaulieu A; Castagnet M; Kraimps JL; Levillain P; Fromont G
    J Endocrinol Invest; 2016 Feb; 39(2):153-8. PubMed ID: 26188382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of EZH1 mutations in the diagnosis of follicular-patterned thyroid tumors.
    Jung CK; Kim Y; Jeon S; Jo K; Lee S; Bae JS
    Hum Pathol; 2018 Nov; 81():9-17. PubMed ID: 29723601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses.
    Nikiforova MN; Biddinger PW; Caudill CM; Kroll TG; Nikiforov YE
    Am J Surg Pathol; 2002 Aug; 26(8):1016-23. PubMed ID: 12170088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular testing for oncogenic gene mutations in thyroid lesions: a case-control validation study in 413 postsurgical specimens.
    Giordano TJ; Beaudenon-Huibregtse S; Shinde R; Langfield L; Vinco M; Laosinchai-Wolf W; Labourier E
    Hum Pathol; 2014 Jul; 45(7):1339-47. PubMed ID: 24830619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
    Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
    Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follicular histotypes of oncocytic thyroid carcinomas do not carry mutations of the BRAF hot-spot.
    Musholt PB; Musholt TJ; Morgenstern SC; Worm K; Sheu SY; Schmid KW
    World J Surg; 2008 May; 32(5):722-8. PubMed ID: 18235983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive survey of HRAS, KRAS, and NRAS mutations in proliferative thyroid lesions from an ethnically diverse population.
    Schulten HJ; Salama S; Al-Ahmadi A; Al-Mansouri Z; Mirza Z; Al-Ghamdi K; Al-Hamour OA; Huwait E; Gari M; Al-Qahtani MH; Al-Maghrabi J
    Anticancer Res; 2013 Nov; 33(11):4779-84. PubMed ID: 24222113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular profile of Hürthle cell carcinomas: recurrent mutations in the Wnt/β-catenin pathway.
    Santana NO; Lerario AM; Schmerling CK; Marui S; Alves VAF; Hoff AO; Kopp P; Danilovic DLS
    Eur J Endocrinol; 2020 Dec; 183(6):647-656. PubMed ID: 33120354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of RET in follicular cell-derived tumors of the thyroid gland: prevalence and implication of morphological type.
    Inaba M; Umemura S; Satoh H; Abe Y; Kurokawa K; Sakai H; Osamura RY
    Pathol Int; 2003 Mar; 53(3):146-53. PubMed ID: 12608895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers.
    Yoo SK; Lee S; Kim SJ; Jee HG; Kim BA; Cho H; Song YS; Cho SW; Won JK; Shin JY; Park do J; Kim JI; Lee KE; Park YJ; Seo JS
    PLoS Genet; 2016 Aug; 12(8):e1006239. PubMed ID: 27494611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors.
    Máximo V; Soares P; Lima J; Cameselle-Teijeiro J; Sobrinho-Simões M
    Am J Pathol; 2002 May; 160(5):1857-65. PubMed ID: 12000737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays.
    Hoos A; Stojadinovic A; Singh B; Dudas ME; Leung DH; Shaha AR; Shah JP; Brennan MF; Cordon-Cardo C; Ghossein R
    Am J Pathol; 2002 Jan; 160(1):175-83. PubMed ID: 11786411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activating BRAF Mutations Detected in Mixed Hürthle Cell Carcinoma and Multifocal Papillary Carcinoma of the Thyroid Gland: Report of an Unusual Case and Review of the Literature.
    Sinno S; Choucair M; Nasrallah M; Wadi L; Jabbour MN; Nassif S
    Int J Surg Pathol; 2016 Sep; 24(6):519-24. PubMed ID: 27006301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.
    Nikiforova MN; Lynch RA; Biddinger PW; Alexander EK; Dorn GW; Tallini G; Kroll TG; Nikiforov YE
    J Clin Endocrinol Metab; 2003 May; 88(5):2318-26. PubMed ID: 12727991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MEN1 mutations in Hürthle cell (oncocytic) thyroid carcinoma.
    Kasaian K; Chindris AM; Wiseman SM; Mungall KL; Zeng T; Tse K; Schein JE; Rivera M; Necela BM; Kachergus JM; Casler JD; Mungall AJ; Moore RA; Marra MA; Copland JA; Thompson EA; Smallridge RC; Jones SJ
    J Clin Endocrinol Metab; 2015 Apr; 100(4):E611-5. PubMed ID: 25625803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of follicular and Hürthle cell neoplasms of the thyroid gland.
    McHenry CR; Sandoval BA
    Surg Oncol Clin N Am; 1998 Oct; 7(4):893-910. PubMed ID: 9735140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hürthle cell tumors: applying molecular markers to define a new management algorithm.
    Maxwell EL; Palme CE; Freeman J
    Arch Otolaryngol Head Neck Surg; 2006 Jan; 132(1):54-8. PubMed ID: 16415430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological differential diagnosis of follicular thyroid tumor and Hürthle cell tumor on the basis of telomere length and hTERT expression.
    Sugishita Y; Kammori M; Yamada O; Yamazaki K; Ito K; Fukumori T; Yoshikawa K; Yamada T
    Ann Surg Oncol; 2014 Jul; 21(7):2318-25. PubMed ID: 24562933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.